Medifast, Inc, through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands.
Read More…
Industry, Sector and Symbol
Industry Miscellaneous food preparations & kindred products
Sub-IndustryPersonal Products
SectorConsumer Staples
Phone410-581-8042
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$713.67 million
Profitability
Miscellaneous
Employees420
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable
Medifast (NYSE:MED) Frequently Asked Questions
What is Medifast's stock symbol?
Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."
How often does Medifast pay dividends? What is the dividend yield for Medifast?
Medifast declared a quarterly dividend on Thursday, December 5th. Stockholders of record on Friday, December 27th will be paid a dividend of $1.13 per share on Thursday, February 6th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 5.44%. The ex-dividend date of this dividend is Thursday, December 26th. This is a boost from Medifast's previous quarterly dividend of $0.75. View Medifast's Dividend History.
How were Medifast's earnings last quarter?
Medifast Inc (NYSE:MED) announced its quarterly earnings results on Wednesday, February, 26th. The specialty retailer reported $1.66 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.07 by $0.59. The specialty retailer had revenue of $170.63 million for the quarter, compared to analysts' expectations of $162 million. Medifast had a return on equity of 60.30% and a net margin of 10.92%. View Medifast's Earnings History.
When is Medifast's next earnings date?
What guidance has Medifast issued on next quarter's earnings?
Medifast issued an update on its FY20 earnings guidance on Wednesday, February, 26th. The company provided EPS guidance of $6.25 to $6.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.84. The company issued revenue guidance of $715.0 million to $745.0 million, compared to the consensus revenue estimate of $798.90 million.
What price target have analysts set for MED?
3 brokers have issued twelve-month target prices for Medifast's shares. Their forecasts range from $83.00 to $90.00. On average, they anticipate Medifast's stock price to reach $86.50 in the next twelve months. This suggests a possible upside of 4.1% from the stock's current price. View Analyst Price Targets for Medifast.
What is the consensus analysts' recommendation for Medifast?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Medifast.
Has Medifast been receiving favorable news coverage?
Media coverage about MED stock has trended very negative on Saturday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Medifast earned a news sentiment score of -4.0 on InfoTrie's scale. They also gave news coverage about the specialty retailer a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Medifast.
Are investors shorting Medifast?
Medifast saw a decline in short interest in January. As of January 31st, there was short interest totalling 3,660,000 shares, a decline of 10.9% from the January 15th total of 4,110,000 shares. Based on an average trading volume of 420,800 shares, the days-to-cover ratio is currently 8.7 days. Currently, 33.1% of the shares of the company are short sold. View Medifast's Current Options Chain.
Who are some of Medifast's key competitors?
What other stocks do shareholders of Medifast own?
Who are Medifast's key executives?
Medifast's management team includes the folowing people:
- Mr. Daniel R. Chard, CEO & Director (Age 54)
- Mr. Timothy G. Robinson CPA, CPA, Chief Financial Officer (Age 57)
- Mr. William Baker IV, Exec. VP of Information Technology (Age 47)
- Mr. Nicholas Johnson, Exec. VP of Coach Success Market Pres of OPTAVIA USA (Age 39)
- Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 48)
Who are Medifast's major shareholders?
Medifast's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (8.03%), Rice Hall James & Associates LLC (3.67%), Pictet Asset Management Ltd. (3.39%), State Street Corp (2.85%), Bank of New York Mellon Corp (2.16%) and Acadian Asset Management LLC (2.10%). Company insiders that own Medifast stock include Carl E Sassano, Charles P Connolly, Constance J Hallquist, Daniel R Chard, Michael A Hoer, Michael C Macdonald and Scott Schlackman. View Institutional Ownership Trends for Medifast.
Which major investors are selling Medifast stock?
MED stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., AQR Capital Management LLC, Acadian Asset Management LLC, Principal Financial Group Inc., Geode Capital Management LLC, Jacobs Levy Equity Management Inc. and Prudential Financial Inc.. Company insiders that have sold Medifast company stock in the last year include Carl E Sassano and Scott Schlackman. View Insider Buying and Selling for Medifast.
Which major investors are buying Medifast stock?
MED stock was purchased by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Bank of New York Mellon Corp, Winmill & CO. Inc., Hotchkis & Wiley Capital Management LLC, Engine Capital Management LP, Snow Capital Management LP, Goodwin Daniel L and Man Group plc. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard and Michael A Hoer. View Insider Buying and Selling for Medifast.
How do I buy shares of Medifast?
Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Medifast's stock price today?
One share of MED stock can currently be purchased for approximately $83.11.
How big of a company is Medifast?
Medifast has a market capitalization of $965.32 million and generates $713.67 million in revenue each year. The specialty retailer earns $55.79 million in net income (profit) each year or $5.96 on an earnings per share basis. Medifast employs 420 workers across the globe.View Additional Information About Medifast.
What is Medifast's official website?
How can I contact Medifast?
Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]
MarketBeat Community Rating for Medifast (NYSE MED)
MarketBeat's community ratings are surveys of what our community members think about Medifast and other stocks. Vote "Outperform" if you believe MED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MED will underperform the S&P 500 over the long term. You may vote once every thirty days.
